Klin Farmakol Farm. 2007;21(1):15-21

CURRENT PHARMACOLOGICAL TREATMENT OPTIONS FOR ERECTILE DYSFUNCTION

doc. MUDr. Vladimír Študent Ph.D, MUDr. Martin Hrabec, MUDr. Igor Hartmann, MUDr. Aleš Vidlář
Urologická klinika FN a LF UP v Olomouci

In male population aged 40–70 years erectile dysfunction occurs in 52 %. The pathological changes by Doppler examination can be found up 90 %, ED can be consider as risk indicator chromíc heart failure, cause of ED can be trauma or iatrogenic damane RRP, TURP. The therapy is not found up 90 % of male. The introduction of new oral therapies has completely changed the diagnostic and therapeutic approuch to ED. We can distinguish drugs with central (yohinbin, apomorphin) and peripheral effect – PDE-5 inhibitors (sildenafil, tadalafil, vardenafil). Oral pharmacotherapy is the first –line therapy. PDE-5 inhibitors are associated with high efficacy and safety.

Keywords: erectile dysfunction, radical prostatectomy, sildenafil, tadalafil

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Študent V, Hrabec M, Hartmann I, Vidlář A. CURRENT PHARMACOLOGICAL TREATMENT OPTIONS FOR ERECTILE DYSFUNCTION. Klin Farmakol Farm. 2007;21(1):15-21.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: result of the Massachusetts Male Aging Study. J.Urol. 1994;151:54-61. Go to original source... Go to PubMed...
    2. Študent V, Fiala R. První výsledky studie KAPROS v Olomouckém kraji, Česká urologie 2006;1:19-22.
    3. Wespes E. a kol. EAU Guidelines on erectile dysfunction. 2006 edition. Go to original source...
    4. Študent V. a kol. Základy urologické andrologie. Praha: Galén 2003.
    5. Bukofzer S, Livesey N. Safety and tolerability of apomorphine SL (Uprima(R)). Int J Impot Res 2001; 13(3):40-44. Go to original source... Go to PubMed...
    6. Castro RM, Curado FJ, López JC. et al. Treatment with sildenafil citrate in renal transplant patients with erectile dysfunction. B.J.U. International 2001;88:241-243. Go to original source... Go to PubMed...
    7. Conti CR, Pepine CJ, Sweeney M. Efficacy and safety of Sildenafil Citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 1999;83:29-34. Go to original source... Go to PubMed...
    8. Guliano F, Hultling C, Wagih S. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury., Ann Neurol 1999; 46:15-21. Go to original source... Go to PubMed...
    9. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J. Neurol. Neurosurg. Psychiatry 2001;71:371-374. Go to original source... Go to PubMed...
    10. Chen J, Mabjeesh NJ, Greenstein A. Clinical Efficacy of Sildenafil in patients on chronic dialysis. J. Urol. 2001; 165:819-821. Go to original source... Go to PubMed...
    11. Jackson G. Sildenafil (Viagra): new data, new confidence in treating erectile dysfunction in the cardiovascular patient. Int. J. Clin. Pract. 2002; 56(2):75. Go to original source... Go to PubMed...
    12. Kloner RA, Mitchell MI, Bedding A, Emmick J. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil. J. Urol. 2002; 167(4):176-177.
    13. Kloner RA, Watkins VS, Costigan TM, Bedding A, Mitchell MI, Emmick J. Cardiovascular profile of tadalafil, a new PDE-5 inhibitor. J. Urol. 2002; 167(4):176.
    14. Kloner RA, Brown M, Prisant LM. Effect of Sildenafil in patients with erectile dysfunction taking antihypertensive therapy. AM. J. Hypertens 2001; 14: 70-73. Go to original source... Go to PubMed...
    15. La Pera G, Pescatori ES, Calabrese M, Boffini A, Colombo F. Peyronie´s Disease: Prevalence and Assotiation with Cigarette Smoking. Eur. Urol. 2001;40:525-530. Go to original source... Go to PubMed...
    16. Mittleman MA, Glasser DB, Orazem J, Collins M. Incidence of myocardial infarction and death in 53 clinical trials of Viagra@ (sildenafil citrate). J. Am. Coll. Cardiol. 2000; 35(Suppl A):806-807.
    17. Patterson B, Bedding A, Jewell H, Payne C, Mitchell M. Dose-normalized pharmacokinetics of tadalafil (IC351) administered as a single oral dose to healthy volunteers. Eur. Urol. 2002; Suppl 1(1):152 [abstract 600]. Go to original source...
    18. Rendell MS, Rajfer J, Wicker P, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes. JAMA 1999; 281(5):421-466. Go to original source... Go to PubMed...
    19. Stark S, Sachse R, Liedl T, Hensen J, Rohde G, Wensing G, Horstmann R, Schrott KM. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single dose. Eur. Urol. 2001; 40:181-190. Go to original source... Go to PubMed...
    20. Virag R, Becher E, Carrier F. et al. Local pharmacological treatment modalities. In:: Jardin A, Wagner G., Khoury S et al. eds. Erectile Dysfunction. Health Publication Ltd 2000; 305-3054.
    21. Zippe CD, Kedia AW, Kedia K, Nelson DR, Agarwal A. Treatment of erectile dysfunction after radical prostatectomy with Sildenafil Citrate (Viagra). Urology 1998; 52:963-966. Go to original source... Go to PubMed...
    22. Zámečník L. Medikamentózní terapie erektilní dysfunkce. Urolog. pro Praxi, 2006; 2:80.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.